Chen et al., 2005 - Google Patents
Patents and development of HBV and HCV clinical treatment: From 2001 to April 2005Chen et al., 2005
- Document ID
- 5019635030983544401
- Author
- Chen Z
- Zheng M
- Publication year
- Publication venue
- Expert Opinion on Therapeutic Patents
External Links
Snippet
This review summarises clinical development and patents, claiming anti-hepatitis B virus (HBV) and anti-hepatitis C virus (HCV) therapy, published from 2001 to April 2004. The majority of patents described in this review are new drugs and new treatment strategies …
- 230000018109 developmental process 0 title abstract description 21
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liang et al. | Present and future therapies of hepatitis B: from discovery to cure | |
| Koumbi | Current and future antiviral drug therapies of hepatitis B chronic infection | |
| Zoulim | Hepatitis B virus resistance to antiviral drugs: where are we going? | |
| Ocama et al. | Hepatitis B virus infection: current status | |
| Manzoor et al. | Hepatitis B virus therapy: What’s the future holding for us? | |
| Conjeevaram et al. | Management of chronic hepatitis B | |
| Kapoor et al. | Strategies to eliminate HBV infection | |
| Brahmania et al. | New therapeutic agents for chronic hepatitis B | |
| Lin et al. | Hepatitis B virus: new therapeutic perspectives | |
| Caviglia et al. | Chronic hepatitis B therapy: available drugs and treatment guidelines. | |
| CN109467566B (en) | Bis-diazabicyclo compounds for use in the treatment and/or prevention of diseases or disorders associated with hepatitis virus | |
| JP2023509869A (en) | Methods of treating viral infections with TLR7 agonists | |
| Stein et al. | Drug targets in hepatitis B virus infection | |
| Cholongitas et al. | Novel therapeutic options for chronic hepatitis C | |
| Neumann | Hepatitis B viral kinetics: a dynamic puzzle still to be resolved | |
| Sun et al. | Investigational drugs with dual activity against HBV and HIV | |
| Singh et al. | Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies | |
| Tang et al. | Strategies to eliminate HBV infection: an update | |
| Balsano et al. | Viral hepatitis B: established and emerging therapies | |
| Wu et al. | Novel approaches towards conquering hepatitis B virus infection | |
| Chen et al. | Patents and development of HBV and HCV clinical treatment: From 2001 to April 2005 | |
| Yuan et al. | Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B | |
| Murray et al. | Variability in long-term hepatitis B virus dynamics under antiviral therapy | |
| Masgala et al. | Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection | |
| ES2381266T3 (en) | Combination therapies of L-FMAU for the treatment of hepatitis B virus infection |